ibi305
Showing 1 - 4 of 4
Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)
Recruiting
- Non-Squamous Non-Small Cell Lung Cancer
- Sintilimab
- +5 more
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Sep 22, 2022
Intrahepatic Cholangiocarcinoma Trial in Tianjin (Sintilimab, IBI305, GEMOX)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Sintilimab
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Feb 22, 2022
Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer Trial (Sintilimab,
Not yet recruiting
- Advanced Microsatellite Stable Colorectal Cancer
- Metastatic Microsatellite-stable Colorectal Cancer
- Sintilimab
- +2 more
- (no location specified)
Feb 3, 2021
Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, IBI305, Sorafenib)
Unknown status
- Hepatocellular Carcinoma
- Sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaHospital of Fudan University
Jan 21, 2021